FindTrial
Sign In

Validation of an online Prognostication Tool(PREDICT Version 2.2 ) In Carcinoma Breast Patients Attending a Cancer Care Centre In Kerala

Validation of PREDICT V 2.2 Breast Cancer Prognostication Tool In Patients attending a Tertiary Cancer Care Centre In Kerala. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/10/059260
Enrollment
896
Registered
2023-10-30
Start date
Unknown
Completion date
Unknown
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

NIL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Non metastatic invasive carcinoma of breast after primary breast conservation surgery or modified radical mastectomy Breast cancer patients who were diagnosed and treated at Caritas cancer institute between 1 st January 2015 and 31 st December2019

Exclusion criteria

Exclusion criteria: Patients with bilateral breast cancer/ ductal carcinoma insitu/ lobular carcinoma in situ Patients who underwent neoadjuvant chemotherapy or endocrine therapy Patient who has breast cancer as second primary Patients with incomplete medicalrecords or missing data necessary for PREDICT tool calculation

Design outcomes

Primary

MeasureTime frame
The accuracy of PREDICT version 2.2 Breast Cancer Prognostication Tool in predicting survival outcomes of study population.Timepoint: 60 months—

Secondary

MeasureTime frame
Local and distant relapse rate of study populationTimepoint: 5 years followup—

Countries

India

Contacts

Public ContactDr Rajitha G

Caritas Cancer Institute, Caritas Hospital and Institute of Health Sciences

druspillai@gmail.com7598563161

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026